BESPONSA® (Inotuzumab ozogamicin)

The FDA on March 6, 2024, approved BESPONSA® for pediatric patients 1 year and older with Relapsed or Refractory CD22-positive B-cell precursor Acute Lymphoblastic Leukemia (ALL). BESPONSA® is a product of Pfizer.